Similar articles

• Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy.

  Urban PP, Wellach I, Faiss S, Layer P, Rosenkranz T, Knop K, Weis J. Urban PP, et al. Mov Disord. 2010 Aug 15;25(11):1748-52. doi: 10.1002/mds.23342. Mov Disord. 2010. PMID: 20740570
• Neuropathy as a potential complication of levodopa use in Parkinson's disease.

  Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D. Toth C, et al. Mov Disord. 2008 Oct 15;23(13):1850-9. doi: 10.1002/mds.22137. Mov Disord. 2008. PMID: 18785232
• Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view.

  Toth C, Suchowersky O, Zochodne D. Toth C, et al. Mov Disord. 2010 Mar 15;25(4):525. doi: 10.1002/mds.22879. Mov Disord. 2010. PMID: 20155864 No abstract available.
• Classifying risk factors for dyskinesia in Parkinson's disease.

  Sharma JC, Bachmann CG, Linazasoro G. Sharma JC, et al. Parkinsonism Relat Disord. 2010 Sep;16(8):490-7. doi: 10.1016/j.parkreldis.2010.06.003. Epub 2010 Jul 3. Parkinsonism Relat Disord. 2010. PMID: 20598622 Review.
• Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.

  Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A. Melamed E, et al. Adv Neurol. 1996;69:545-50. Adv Neurol. 1996. PMID: 8615179 Review. No abstract available.